Chinese herbs show promise for lung cancer, flu, and idiopathic pulmonary fibrosis

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza.

In three separate studies, researchers from China Academy of Chinese Medical Science in Beijing analyzed the health benefits of on patients with NSCLC, IPF, and seasonal influenza.

Researchers found that JHQG helped to prolong survival in patients with metastatic NSCLC compared with patients receiving standard care; was safe and effective in the management of IPF and could also help improve patients' quality of life and activity capacity; and helped to reduce fever in patients with influenza compared with placebo.

Researchers conclude that Chinese herbs could be used as an alternative treatment for the aforementioned conditions.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Hope for patients with mild idiopathic pulmonary fibrosis

May 18, 2010

A new therapy shows promise for patients with mild idiopathic pulmonary fibrosis. According to researchers in Japan, inhaled N-acetylcysteine (NAC) monotherapy preserves more lung function in some idiopathic pulmonary fibrosis ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.